JP2007523089A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523089A5
JP2007523089A5 JP2006553342A JP2006553342A JP2007523089A5 JP 2007523089 A5 JP2007523089 A5 JP 2007523089A5 JP 2006553342 A JP2006553342 A JP 2006553342A JP 2006553342 A JP2006553342 A JP 2006553342A JP 2007523089 A5 JP2007523089 A5 JP 2007523089A5
Authority
JP
Japan
Prior art keywords
composition
nucleic acid
binding
antagonist
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006553342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523089A (ja
JP4949859B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/004743 external-priority patent/WO2005079844A2/en
Publication of JP2007523089A publication Critical patent/JP2007523089A/ja
Publication of JP2007523089A5 publication Critical patent/JP2007523089A5/ja
Application granted granted Critical
Publication of JP4949859B2 publication Critical patent/JP4949859B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006553342A 2004-02-17 2005-02-15 インターロイキン−33(il33)およびil−33レセプター複合体の使用 Expired - Lifetime JP4949859B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54573004P 2004-02-17 2004-02-17
US60/545,730 2004-02-17
PCT/US2005/004743 WO2005079844A2 (en) 2004-02-17 2005-02-15 Use for interleukin-33 (il33) and the il-33 receptor complex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011131646A Division JP2011178810A (ja) 2004-02-17 2011-06-13 インターロイキン−33(il33)およびil−33レセプター複合体の使用

Publications (3)

Publication Number Publication Date
JP2007523089A JP2007523089A (ja) 2007-08-16
JP2007523089A5 true JP2007523089A5 (cg-RX-API-DMAC7.html) 2008-03-21
JP4949859B2 JP4949859B2 (ja) 2012-06-13

Family

ID=34886190

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006553342A Expired - Lifetime JP4949859B2 (ja) 2004-02-17 2005-02-15 インターロイキン−33(il33)およびil−33レセプター複合体の使用
JP2011131646A Pending JP2011178810A (ja) 2004-02-17 2011-06-13 インターロイキン−33(il33)およびil−33レセプター複合体の使用
JP2014030239A Pending JP2014098026A (ja) 2004-02-17 2014-02-20 インターロイキン−33(il33)およびil−33レセプター複合体の使用
JP2015163939A Pending JP2016034948A (ja) 2004-02-17 2015-08-21 インターロイキン−33(il33)およびil−33レセプター複合体の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011131646A Pending JP2011178810A (ja) 2004-02-17 2011-06-13 インターロイキン−33(il33)およびil−33レセプター複合体の使用
JP2014030239A Pending JP2014098026A (ja) 2004-02-17 2014-02-20 インターロイキン−33(il33)およびil−33レセプター複合体の使用
JP2015163939A Pending JP2016034948A (ja) 2004-02-17 2015-08-21 インターロイキン−33(il33)およびil−33レセプター複合体の使用

Country Status (14)

Country Link
US (5) US20050203046A1 (cg-RX-API-DMAC7.html)
EP (2) EP1725261B1 (cg-RX-API-DMAC7.html)
JP (4) JP4949859B2 (cg-RX-API-DMAC7.html)
CN (1) CN1917902A (cg-RX-API-DMAC7.html)
AT (1) ATE496636T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005215528B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507808A (cg-RX-API-DMAC7.html)
CA (1) CA2555236C (cg-RX-API-DMAC7.html)
DE (1) DE602005026105D1 (cg-RX-API-DMAC7.html)
NO (1) NO20064193L (cg-RX-API-DMAC7.html)
NZ (1) NZ549040A (cg-RX-API-DMAC7.html)
TW (2) TWI372628B (cg-RX-API-DMAC7.html)
WO (1) WO2005079844A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606844B (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2009511572A (ja) * 2005-10-16 2009-03-19 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 炎症性皮膚疾患、障害または症状のための医薬組成物および診断方法
PL2386860T4 (pl) * 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
DK2482078T3 (en) 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
SI2019965T1 (sl) * 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
SE532250C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) * 2007-05-18 2010-08-19 メディミューン,エルエルシー 炎症性疾患におけるil−33
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
JP5539660B2 (ja) * 2009-03-10 2014-07-02 公益財団法人ヒューマンサイエンス振興財団 粘膜ワクチン用アジュバント
EP2475388B1 (en) * 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
ES2549637T3 (es) * 2011-02-23 2015-10-30 F. Hoffmann-La Roche Ag Anticuerpos contra IL33R humano y la utilización de los mismos
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
IN2015DN01767A (cg-RX-API-DMAC7.html) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
US10703799B2 (en) 2012-12-10 2020-07-07 Vib Vzw IL-33R and IL-1RAcP fusion proteins
WO2014126277A1 (ko) * 2013-02-14 2014-08-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
WO2014128254A1 (en) * 2013-02-22 2014-08-28 University Of Eastern Finland (Kuopion Kampus) Il-33 and treatment of neurodegenerative diseases
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP2968392B1 (en) 2013-03-15 2020-08-05 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejuvenating human cells
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−33拮抗薬とその使用法
US9840545B2 (en) 2013-09-20 2017-12-12 University Of Virginia Patent Foundation Fusion protein comprising interleukin-2 and interleukin-33
AU2014332352B9 (en) * 2013-10-07 2017-05-11 Inovio Pharmaceuticals, Inc. Vaccines with Interleukin-33 as an adjuvant
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
CA2946511C (en) 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック, インコーポレイテッド 抗インターロイキン−33抗体及びその使用
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
WO2016140921A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
WO2016138590A1 (en) * 2015-03-03 2016-09-09 Wilfred Jefferies Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗il−33中和モノクローナル抗体
US10813979B2 (en) * 2015-07-10 2020-10-27 The Hong Kong University Of Science And Technology Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
JP6858182B2 (ja) * 2015-10-06 2021-04-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用
KR101765397B1 (ko) 2015-12-02 2017-08-07 한국과학기술원 질점막을 통한 바이러스 감염 취약 진단 마커로서의 il-33의 용도
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JP7148414B2 (ja) 2016-06-29 2022-10-05 チェックポイント セラピューティクス,インコーポレイテッド Pd-l1特異的抗体およびそれを使用する方法
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CN116715775A (zh) 2017-02-10 2023-09-08 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
EP3582802A4 (en) * 2017-02-17 2021-02-17 The General Hospital Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF A BRAIN INJURY
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
KR102872720B1 (ko) 2017-05-05 2025-10-16 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 기질 결합 소낭의 안구에의 적용
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Il-33アンタゴニストを含む子宮内膜症治療剤
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
IL307286B2 (en) 2018-04-11 2026-03-01 Regeneron Pharma Methods and compositions for quantifying il-33
EP3787642A4 (en) * 2018-05-03 2022-09-21 University of Pittsburgh - of the Commonwealth System of Higher Education IL-33 CONTAINING MATRIX-BONDED VESICLES (MBVS) AND THEIR USE
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109139A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
TWI861073B (zh) 2019-03-21 2024-11-11 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021003138A1 (en) * 2019-06-30 2021-01-07 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of pancreatic cancer
WO2021068196A1 (en) * 2019-10-11 2021-04-15 General Regeneratives (Shanghai) Limited Methods of using il-33 protein in treating cancers
JP7843701B2 (ja) * 2019-11-04 2026-04-10 メディミューン リミテッド Il-33アンタゴニストの使用方法
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
CN112210556A (zh) * 2020-10-15 2021-01-12 扬州大学 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用
WO2022164976A2 (en) * 2021-01-27 2022-08-04 The Trustees Of Dartmouth College Immunostimulatory cytokine combination and therapeutic use thereof
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN114426981B (zh) * 2022-02-21 2022-11-29 吉林农业大学 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
CN118185884A (zh) * 2023-10-16 2024-06-14 王琪 负载il33的溶瘤痘苗病毒及其与免疫检查点抑制剂的联合疗法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
WO1992010210A1 (en) * 1990-12-14 1992-06-25 E.I. Du Pont De Nemours And Company Inhibition of angiogenesis by il-1
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
WO1999032626A1 (en) * 1997-12-23 1999-07-01 Immunex Corporation Sigirr dna and polypeptides
GB9727172D0 (en) * 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001046697A2 (en) 1999-12-21 2001-06-28 Millennium Predictive Medicine Identification, assessment, prevention, and therapy of breast cancer
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2431861A1 (en) 2000-12-08 2002-06-13 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
AU2001289843A1 (en) 2001-08-28 2002-02-13 Bayer Cropscience Ag Polypeptides for identifying herbicidally active compounds
AU2003299441A1 (en) * 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
EP1759010A4 (en) 2004-01-07 2008-12-24 Bristol Myers Squibb Co BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン,エルエルシー 炎症性疾患におけるil−33

Similar Documents

Publication Publication Date Title
US20260049993A1 (en) Viral serology assays
US20230204568A1 (en) Measuring trail by lateral flow immunoassay
US20210389308A1 (en) Detecting adaptive immunity to coronavirus
US20210405059A1 (en) Biomarkers for early determination of a critical or life threatening response to illness and/or treatment response
EP4141448A1 (en) Protein signatures for distinguishing between bacterial and viral infections
ES2683854T3 (es) Un método para determinar biomarcadores relacionados con el síndrome de distrés respiratorio agudo (ARDS), un método para monitorizar el desarrollo y tratamiento de ARDS en un paciente
AU2016210996B2 (en) Therapeutic target and biomarker in IBD
US8367350B2 (en) Compositions and methods for diagnosis, prognosis and management of malaria
Gupta et al. Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
US20170234873A1 (en) Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP4184167A1 (en) Early diagnosis of infections
WO2010025393A2 (en) Protein biomarkers and methods for diagnosing kawasaki disease
Desplat-Jégo et al. Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry
JP2007523088A5 (cg-RX-API-DMAC7.html)
EP3183582A2 (en) Biomarkers for diagnosis and management of neuro-immunological diseases
CN111133313A (zh) 评估生物药物治疗的受试者中的中和性抗体水平的测定及其在个性化医疗中的用途
RU2018108831A (ru) Биомаркеры для лечения очаговой алопеции
CN102884433A (zh) 用于检测抗体的方法
US20160231333A1 (en) Biomarkers for Tuberculosis
EP3289358A1 (en) Novel design of enzyme-linked immunsorbent assay plates and systems and methods of use thereof
CN105849566A (zh) 肾脏疾病生物标志物
CN111954814A (zh) 定量il-33的方法和组合物
WO2013114064A1 (en) Methods and devices for diagnosis of serious bacterial infection
WO2023034933A1 (en) Methods and systems for assessing adaptive immunity to coronavirus
EP3827098A1 (en) Method of diagnosing asthma subtypes